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Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA) play an important
role in stress-induced cocaine-seeking behavior. We provide evidence for pharmacologically significant interactions between CRF and
orexin-A that depend on oligomerization of CRF1 receptor (CRF1R) and orexin OX1 receptors (OX1R). CRF1R–OX1R heteromers are the
conduits of a negative crosstalk between orexin-A and CRF as demonstrated in transfected cells and rat VTA, in which they significantly
modulate dendritic dopamine release. The cocaine target 1 receptor (1R) also associates with the CRF1R–OX1R heteromer. Cocaine
binding to the 1R–CRF1R–OX1R complex promotes a long-term disruption of the orexin-A–CRF negative crosstalk. Through this
mechanism, cocaine sensitizes VTA cells to the excitatory effects of both CRF and orexin-A, thus providing amechanism bywhich stress
induces cocaine seeking.
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Introduction
The 41 aa neuropeptide corticotropin-releasing factor (CRF)
plays an important role in stress-induced drug-seeking behavior
(Sarnyai et al., 2001). This depends primarily on CRF release in
the ventral tegmental area (VTA), which receives CRF inputs
from the paraventricular nucleus and the limbic forebrain (Ro-
daros et al., 2007). Stress and addictive drugs sensitize VTA
dopaminergic neurons to the effects of excitatory inputs by com-
mon synaptic modifications (Saal et al., 2003), which can be re-
produced byVTAapplication ofCRF (Ungless et al., 2003). In the
VTA of cocaine-experienced but not naive animals, stress-
induced CRF release increases extracellular levels of glutamate
and dopamine (Wang et al., 2005, 2007). Of the two known CRF
receptors (CRF1R and CRF2R), CRF1R is involved preferentially
with stress-induced reinstatement of cocaine-seeking behavior
and VTA dopamine release (Shaham et al., 1998; Lu et al., 2003;
Lodge and Grace, 2005; Blacktop et al., 2011).
The 33- and 28-aa-long neuropeptides orexin-A (hypocretin-A)
and orexin-B (hypocretin-B) are expressed within cell bodies in the
lateral hypothalamus and adjacent perifornical area (Sakurai et
al., 1998; de Lecea et al., 1998). These cells are the origin of an
ascending arousal system that projects to the entire cortex, but
apart from their well established role in arousal, orexins have a
role in reward processes and substance-use disorders, which
might depend on the dense orexinergic innervation of the dopa-
minergic cells of the VTA (Borgland et al., 2010; Mahler et al.,
2014; Sakurai, 2014). A dichotomy in orexin function appears to
be related to the two identified orexin receptors, with reward and
arousal being associated closely with activation of OX1R and
OX2R, respectively (Borgland et al., 2010; Mahler et al., 2014).
The orexin–hypocretin system also drives cocaine reinstatement
through activation of stress pathways, which includes the partic-
ipation of CRF. Thus, central administration of orexin-A led to a
dose-related reinstatement of cocaine seeking, which was pre-
vented by a nonselective CRFR antagonist, and a selective OX1R
Received Oct. 21, 2014; revised Feb. 18, 2015; accepted Feb. 23, 2015.
Author contributions: G.N., D.M.-D., C.Q., W.R., N.-S.C., D.A., L.A.H., F.H., A.C., J.M., V.C., C.L., E.I.C., S.F., and
P.J.M. designed research; G.N., D.M.-D., C.Q., A.S., K.M., W.P.R., E.M., and P.J.M. performed research; G.N., D.M.-D.,
C.Q., W.R., E.M., C.L., S.F., and P.J.M. analyzed data; G.N., D.M.-D., C.Q., C.L., S.F., and P.J.M. wrote the paper.
This work was supported by intramural funds of the National Institute on Drug Abuse, from Spanish Ministry of
Science and Technology Grants SAF2011-23813 and SAF2009-07276, Government of Catalonia Grant 2009-SGR-12,
and Center for Biomedical Research in Neurodegenerative Diseases Network Grant CB06/05/0064. P.J.M. was sup-
ported through a Ramo´n y Cajal Fellowship. We thank Jasmina Jime´nez for technical assistance.
The authors declare no competing financial interests.
*G.N., C.Q., and D.M.D. contributed equally to this manuscript.
†E.I.C., S.F., and P.J.M. are senior co-authors.
Correspondence should be addressed to either of the following: Dr. Sergi Ferre´, IntegrativeNeurobiology Section,
National Institute on Drug Abuse, Intramural Research Program, Triad Technology Building, 333 Cassell Drive,
Baltimore,MD21224, E-mail: sferre@intra.nida.nih.gov; orDr. Peter J.McCormick, School of Pharmacy,University of
East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK. E-mail: p.mccormick@uea.ac.uk.
DOI:10.1523/JNEUROSCI.4364-14.2015
Copyright © 2015 the authors 0270-6474/15/356639-15$15.00/0
The Journal of Neuroscience, April 29, 2015 • 35(17):6639–6653 • 6639
antagonist blocked stress-induced reinstatement of previously
extinguished cocaine-seeking behavior (Boutrel et al., 2005).
The same as for CRF, VTA is a key brain area involved in the
ability of the orexinergic system to promote cocaine seeking.
Intra-VTA administration of orexin-A reinstated cocaine self-
administration, which was also associated with VTA glutamate
and dopamine release (Wang et al., 2009). Intriguingly, although
CRF and orexin-A are involved in stress-induced cocaine rein-
statement by acting in the VTA, their mechanisms appeared in-
dependent (Wang et al., 2009). In the present study, we provide
evidence for the existence of pharmacologically significant inter-
actions betweenCRF and orexin-A that depend onCRF1R–OX1R
oligomerization. CRF1R–OX1R heteromers are the conduits of a
negative crosstalk between orexin-A and CRF observed in trans-
fected cells and theVTA, inwhich they can significantly influence
dendritic dopamine release. We also demonstrate that CRF1R–
OX1R heteromers associate with 1 receptors (1Rs) to form
CRF1R–OX1R-1R complexes and that cocaine binding to1R in
the complex promotes a long-term disruption of the orexin-A–
CRF negative crosstalk. Through this mechanism, cocaine sensi-
tizes VTA cells to the excitatory effects of bothCRF and orexin-A.
Materials andMethods
Ligands and HIV transactivator of transcription-linked peptides. ()-
CocaineHCl was purchased from Sigma and from the Spanish Agency of
Medicine (number 2003C00220). 1R ligands PD144418 (1,2,3,6-
tetrahydro-5-[3-(4-methylphenyl)-5-isoxazolyl]-1-propylpyridineoxalate)and
PRE-084 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate hydrochlo-
ride,CRF, orexins, SB334867 (N-(2-Methyl-6-benzoxazolyl)-N-1,5-naphthyri-
din-4-yl urea), and NBI27914 [5-chloro-N-(cyclopropylmethyl)-2-methyl-N-
propyl-N-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride]
werepurchasedfromTocrisBioscience.Toallowintracellulardelivery,apeptide
or protein can be fused to the cell-penetrating HIV transactivator of transcrip-
tion (TAT) peptide (YGRKKRRQRRR; Schwarze et al., 1999). HIV TAT
fused to a peptide with the amino acid sequence of a transmembrane
domain (TM) of a GPCR can be inserted effectively into the plasma
membrane as a result of both the penetration capacity of the TAT
peptide and the hydrophobic property of the TM domain (He et al.,
2011). HIV TAT-fused peptides with the amino acid sequences of
OX1R TM domains TM1, TM5, and TM7 were used (Genemad Syn-
thesis). To obtain the right orientation of the inserted peptide, HIV
TAT peptide was fused to the C terminus of OX1R TM1, TM5, and




Expression vectors, fusion proteins, and CRF1R mutants. Sequences en-
coding amino acid residues 1-155 and 156-238 of yellow fluorescent
protein (YFP) Venus protein were subcloned in pcDNA3.1 vector to
obtain YFP Venus hemitruncated proteins. Human cDNAs for OX1R,
CRF1R, ghrelin 1a receptors [growth hormone secretagogue 1a receptor
(GHS1aR)], or 1R, cloned into pcDNA3.1, were amplified without their
stop codons using sense and antisense primers harboring the follow-
ing: EcoRI and KpnI sites to clone CRF1R, OX1R, or GHS1aR in
pcDNA3.1RLuc vector (pRLuc–N1; PerkinElmer Life and Analytical Sci-
ences) or pEYFP–N1 vector (enhanced yellow variant of GFP; Clontech),
HindIII andBamHI sites to clone1R in pEYFP–N1 vector, or EcoRI and
BamHI sites to clone CRF1Rs and OX1Rs in a Cherry containing vector
(pcDNA3.1Cherry). Amplified fragments were subcloned to be in-frame
with restriction sites of pRLuc–N1, pEYFP–N1, or pcDNA3.1Cherry vec-
tors to provide plasmids that express proteins fused to Renilla Luciferase
(RLuc), YFP, or Cherry on the C-terminal end (OX1R–RLuc, CRF1R–
RLuc, OX1R–YFP, CRF1R–YFP, GHS1aR–YFP, 1R–YFP, or CRF1R–
Cherry). Dr. Marian Castro (University of Santiago de Compostela,
Santiago de Compostela, Spain) generously provided human -arrestin
2–RLuc6 cDNA, cloned in pcDNA3.1 RLuc6 vector (pRLuc–N1;
PerkinElmer Life and Analytical Sciences). For bimolecular fluorescence
complementation (BiFC) experiments, human cDNA for CRF1R was
also subcloned into pcDNA3.1–nVenus to provide a plasmid that ex-
presses the receptor fused to the hemitruncated nYFP Venus on the
C-terminal end of the receptor (CRF1R–nVenus), and human cDNA for
OX1R was also subcloned into pcDNA3.1–cVenus to provide a plasmid
that expresses the receptor fused to the hemitruncated cYFP Venus on
the C-terminal end of the receptor (OX1R–cVenus). Two CRF1R mu-
tants were used: (1) CRF1R433, which lacks a large portion of the extra-
cellular domain of the N terminus (amino acids 1–111) and is not able to
bind ligands (Devigny et al., 2011); and (2) CRF1R432, with H405P and
A119L mutations in the 3 IL that confer enhanced constitutive activity.
Cell clones, cell culture, and transient transfection.HEK-293T cells were
grown in DMEM (Gibco) supplemented with 2 mM L-glutamine, 100
g/ml sodium pyruvate, 100 U/ml penicillin/streptomycin, minimal es-
sentialmediumnon-essential amino acids solution (1:100), and 5% (v/v)
heat-inactivated fetal bovine serum (Invitrogen) and were maintained at
37°C in an atmosphere with 5% CO2. Cells were transiently transfected
with the corresponding fusion protein cDNA by the polyethylenimine
(Sigma) method. For receptor–heteromer signaling, 0.4 g of OX1R–
RLuc cDNA and 0.3 g of CRF1R–YFP cDNA were transfected, which
provides 80–90% of maximum bioluminescence resonance energy
transfer (BRET), as deduced from the BRET saturation curves (Fig. 1),
indicating a high degree of receptor heteromerization. For the expression
of GHS1aR–YFP, equal amounts of GHS1aR–YFP and GHS1bR cDNA
were transfected to ensure GHS1aR expression at the cell membrane.
HEK-293T stable cell lines expressing CRF1R–YFP or OX1R–YFP fusion
proteins were created by transfection of the corresponding cDNA in a
pcDNA3.1 plasmid. Antibiotic-resistant clones were isolated with 1000
g/ml geneticin (Invitrogen), and, after an appropriate number of pas-
sages, stable cell lines were selected and grown as above indicated in the
presence of 500 g/ml geneticin. Sample protein concentration was de-
termined as a control of cell number using a Bradford assay kit (Bio-Rad)
with bovine serum albumin (BSA) dilutions as standards.
Fluorescence complementation assays. HEK-293T cells were cotrans-
fected with 0.6 M CRF1R–nVenus cDNA and 0.6 M OX1R–cVenus
cDNA; 48 h after transfection, cells were treated or not with the indicated
HIV TAT–TM-fused peptides (4 M) for 60 min at 37°C. To quantify
protein-reconstituted YFP Venus expression, cells (20 g of protein)
were distributed in 96-well microplates (black plates with a transparent
bottom; Porvair), and fluorescence was read in a Fluo Star Optima Flu-
orimeter (BMGLabtech) equipped with a high-energy xenon flash lamp,
using a 10 nm bandwidth excitation filter at 400 nm reading. Protein
fluorescence expression was determined as fluorescence of the sample
minus the fluorescence of cells not expressing the fusion proteins.
Resonance energy transfer experiments. For BRET assays, HEK-293T
cells were transiently cotransfected with a constant amount of cDNA
encoding for proteins fused to RLuc and with increasing amounts of the
cDNA corresponding to proteins fused to YFP. To quantify protein YFP
expression, cells (20 g of protein) were distributed in 96-well micro-
plates (black plates with a transparent bottom), and fluorescence was
read in the Fluo Star Optima Fluorimeter using a 10 nm bandwidth
excitation filter at 400 nm reading. Protein fluorescence expression was
determined as fluorescence of the sample minus the fluorescence of cells
expressing the BRET donor alone. For BRET measurements, the equiv-
alent of 20 g of cell suspension were distributed in 96-well microplates
(Corning 3600, white plates; Sigma), and coelenterazine H (5 M; Invit-
rogen) was added. After 1 min, readings were obtained using a Mithras
LB 940 (Berthold Technologies) that allows the integration of the signals
detected in the short-wavelength filter at 485 nm and the long-
wavelength filter at 530 nm. To quantify protein RLuc expression lumi-
nescence, readings were also performed 10 min after addition of
coelenterazine H (5 M). For sequential resonance energy transfer
(SRET) assays, HEK-293T cells were transiently cotransfected with con-
stant amounts of cDNAs encoding for both receptor fused to RLuc and
YFP proteins and with increasingly amounts of cDNA corresponding to
the receptor fused to Cherry protein. After 48 h of transfection, quanti-
fications were performed in parallel in aliquots of transfected cells (20g
of protein): (1) quantification of receptor YFP or receptor RLuc expres-
sion was performed as indicated for BRET experiments; (2) for quanti-
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fication of receptor Cherry expression, cells were distributed in 96-well
microplates (Corning black plates with a transparent bottom), and fluo-
rescence was read in the Fluo Star Optima Fluorimeter using a 10 nm
bandwidth excitation filter at 590-nm reading; and (3) for quantification
of SRET, cells were distributed in 96-wellmicroplates (black plates with a
transparent bottom), and coelenterazine H (5 M) was added. After 1
min, the readings were collected using a using a Fluo Star Optima Fluo-
rimeter that allows the integration of the signals detected in the short-
wavelength filter at 530 nm and the long-wavelength filter at 590 nm.Net
BRET and net SRET were defined as [(long-wavelength emission)/
(short-wavelength emission)]  Cf, where Cf corresponds to [(long-
wavelength emission)/(short-wavelength emission)] for the donor
construct expressed alone in the same experiment. Both fluorescence and
luminescence of each sample were measured before every experiment to
confirm similar donor expressions (100,000 bioluminescence units)
while monitoring the increase in acceptor expression (1000–40,000 flu-
orescence units). BRET or SRET was expressed as milliBRET (mBU) or
milliSRET (mSU) units (net BRET or SRET 1000). Data were fitted to
a nonlinear regression equation, assuming a single-phase saturation
curve with GraphPad Prism software (GraphPad Software). The relative
amount of BRET or SRET is given as a function of 100  the ratio
between the fluorescence of the acceptor (YFP or Cherry) and the Lu-
ciferase activity of the donor (RLuc).
Proximity ligation assay. For proximity ligation assays (PLAs), trans-
fected cells were grown on glass coverslips and were fixed in 4% parafor-
maldehyde for 15 min, washed with PBS containing 20 mM glycine,
permeabilized with the same buffer containing 0.05% Triton X-100, and
washed successively with PBS. Heteromers were detected using the
Duolink II in situ PLA detection Kit (OLink Bioscience) following the
instructions of the supplier. To detect both OX1R–RLuc–CRF1R–YFP
andOX1R–RLuc–GHS1aR–YFP heteromers, amixture of equal amounts
of rabbit anti-RLuc antibody (EMDMillipore) and mouse anti-YFP an-
tibody (Santa Cruz Biotechnology) was used and incubated with anti-
rabbit plus and anti-mouseminus PLAprobes. Cells weremounted using
the mounting mediumwith DAPI. The samples were observed in a Leica
SP2 confocal microscope equipped with an apochromatic 63 oil-
immersion objective (numerical aperture 1.4) and 405 and 561 nm laser
lines. For each field of view, a stack of two channels (one per staining) and
9–15Z stackswith a step size of 1mwere acquired. Imageswere opened
and processed with NIH Image J confocal.
Immunocytochemistry.Cells were fixed in 4%paraformaldehyde for 15
min andwashedwith PBS containing 20mMglycine (buffer A) to quench
the aldehyde groups. After permeabilization with buffer A containing
0.2% Triton X-100 for 5 min, cells were treated with PBS containing 1%
BSA. After 1 h at room temperature, cells were labeled with the primary
mouse monoclonal anti-RLuc receptor antibody (1:200; Millipore) for
1 h to detect OX1R–RLuc, washed, and stained with the secondary Cy3
donkey anti-mouse antibody (1:200; Jackson ImmunoResearch). CRF1R
fused to YFP protein were detected by their fluorescence properties. The
samples were rinsed several times and mounted with a medium suitable
for immunofluorescence (30%Mowiol; Calbiochem). Samples were ob-
served in a Leica SP2 confocal microscope.
Rat VTA slices.Male Sprague Dawley rats (2 months old; animal facil-
ity of the Faculty of Biology, University of Barcelona) were used. The
Figure1. CRF1R–OX1Rheteromers in transfectedHEK-293T cells.A, BRET saturation experiments in cells transfectedwithOX1R–RLuc cDNA (0.4g) and increasing amounts of CRF1R–YFP cDNA
(0.05–0.5g). Low and linear BRET is observed in cells transfected with OX1R–RLuc cDNA (0.4g) and GHS1aR–YFP cDNA (0.4–2g). BRET, expressed as mBU, is given as a function of 1000
ratio of fluorescence of the acceptor (YFP) and Luciferase activity of the donor (Rluc). Values are means SEMs of six to seven replications of one independent experiment per point. B, Confocal
microscopy images (superimposed sections) from PLA experiments performed in HEK-293T cells transfected with CRF1R–YFP cDNA (0.3g) and OX1R–RLuc cDNA (0.4g) (left) or GHS1aR–YFP
cDNA (2g) andOX1R–RLuc cDNA (0.4g) (right). Heteromeric complexes appear as red spots and cell nuclei in blue (DAPI stained). Scale bars, 20m. C, Confocalmicroscopy images of HEK-293T
cells transfected with CRF1R–YFP cDNA (0.3g; left), OX1R–RLuc cDNA (0.4g; middle), or GSH1aR–YFP (2g; right). YFP-fused receptors are identified by their own fluorescence (green) and
OX1R–RLuc by immunocytochemistry (red). Scale bars, 10m. D, ERK1/2 phosphorylation in HEK-293T cells transfected with CRF1R, CRF1R–RLuc, or CRF1R–YFP cDNA (0.3g; white columns) or
with OX1R, OX1R–RLuc, or OX1R–YFP cDNA (0.4g; black columns)were treatedwith CRF (100 nM) or orexin-A (50 nM), respectively. Values aremeans SEMs of seven experiments per group and
are expressed as percentage of basal levels (100%). One-wayANOVA followedby Bonferroni’smultiple comparison post hoc test shows significant agonist effect versus basal values (**p 0.01 and
***p 0.001). Representative Western blots are at the bottom.
Navarro et al. • Orexin–CRF Receptor Heteromers in the VTA J. Neurosci., April 29, 2015 • 35(17):6639–6653 • 6641
animals were housed twoper cage and kept on a 12 h dark/light cyclewith
food and water available ad libitum, and experiments were performed
during the light cycle. All procedures were approved by the Catalan Eth-
ical Committee for Animal Use (CEAA/DMAH4049 and 5664). Animals
were killed by decapitation under 4% isoflurane anesthesia, and brains
were rapidly removed, placed in ice-cold oxygenated (O2/CO2, 95%/5%)
Krebs–HCO3
 buffer (in mM: 124 NaCl, 4 KCl, 1.25 KH2PO4, 1.5 MgCl2,
1.5 CaCl2, 10 glucose, and 26 NaHCO3, pH 7.4), and sliced at 4°C using
a brain matrix (Zivic Instruments). VTA slices (500m thick) were kept
at 4°C in Krebs–HCO3
 buffer during the dissection; each slice was trans-
ferred into a 12-well plate with Corning Netwell inserts, containing 2 ml
of ice-cold Krebs–HCO3
 buffer. The temperature was raised to 23°C,
and, after 30 min, the medium was replaced by 2 ml of fresh Krebs–
HCO3
 buffer (23°C). Slices were incubated under constant oxygenation
(O2/CO2, 95%/5%) at 30°C for 4 h in an Eppendorf Thermomixer (5
Prime), and the medium was replaced by fresh Krebs–HCO3
 buffer and
incubated for 30 min before the addition of any agent. After incubation,
the solutionwas discarded, and slices were frozen on dry ice and stored at
80°C until ERK1/2 phosphorylation was determined.
Akt andERK1/2 phosphorylation.Cells or rat VTA sliceswere treated or
notwith the indicated ligands for the indicated time andwere lysed by the
addition of 300 l of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 50
mMNaF, 150mMNaCl, 45mM-glycerophosphate, 1%TritonX-100, 20
M phenyl-arsine oxide, 0.4 mM NaVO4, and protease inhibitor mix-
ture). Cellular debris was removed by centrifugation at 13,000 g for 5
min at 4°C, and the protein was quantified by the bicinchoninic acid
methodusingBSAdilutions as standard. Akt or ERK1/2 phosphorylation
was then determined byWestern blot as described previously (Moreno et
al., 2014), using a rabbit anti-phospho-Ser473 Akt antibody (1:2500;
Signalway Antibody) for Akt phosphorylation or mouse anti-phospho-
ERK1/2 antibody (1:2500; Sigma) and rabbit anti-ERK1/2 antibody that
recognizes both phosphorylated and nonphosphorylated ERK1/2 (1:
40,000; Sigma).
-Arrestin 2 recruitment. Arrestin recruitment was determined as de-
scribed previously (Moreno et al., 2014). Briefly, BRET experiments were
performed in HEK-293T cells 48 h after transfection with the cDNA
corresponding to the indicated receptors fused or not to the YFP and
-arrestin 2–RLuc cDNA (0.5g). Cells (20g protein) were distributed
in 96-well microplates (Corning 3600, white plates with white bottom;
Sigma) and were incubated with the indicated antagonist for 10 min and
stimulated with the agonist for 10 min before the addition of coelentera-
zineH (5M; Invitrogen). After 1min of adding coelenterazineH, BRET
between-arrestin 2–RLuc and receptor YFPwas determined and quan-
tified as described above.
cAMP production.TransfectedHEK-293T cells were incubated in serum-
freemedium for 16 h before the experiment. Cells were preincubated for 15
min at 37°C with zardaverine (50M; Tocris Bioscience) and treated for 15
min with the indicated concentration of agonists in the presence or absence
of forskolin (0.5 M; Sigma). When indicated, receptor antagonists were
preincubated10minbefore agonist addition.To stop the reaction, cellswere
placed on ice, washed with ice-cold PBS, and centrifuged at 2500 g for 5
min at 4°C. The pellet was washed with ice-cold HBSS with 10 mM glucose
and resuspendedwith200l ofHClO4 (4%) for 30min, and1.5MKOHwas
added to reach neutral pH. Samples were centrifuged at 15,000 g for 30
min at 4°C, and the supernatant was frozen at 20°C. Accumulation of
cAMPwasmeasured with Cyclic AMP (3H) Assay System (GEHealthcare)
as described by the manufacturer.
Dynamicmass redistribution assays.Dynamicmass redistribution (DMR)
was determined using an EnSpire Multimode Plate Reader (PerkinElmer
Life and Analytical Sciences). Refractive waveguide grating optical biosen-
sors, integrated in 384-well microplates, allow extremely sensitive measure-
ments of changes in local optical density in a detecting zone up to 150 nm
above the surface of the sensor. Cellular mass movements induced during
receptor activation were detected by illuminating the underside of the bio-
sensor with polychromatic light and measured as changes in wavelength of
the reflectedmonochromatic light that is a sensitive function of the index of
refraction. Themagnitude of thiswavelength shift (in picometers) is directly
proportional to the amount ofDMR.Briefly, 24hbefore the assay, cellswere
seeded at a density of 5000 cells per well in 384-well sensormicroplates with
30 l of growth medium and cultured for 24 h (37°C, 5% CO2) to obtain
70–80% confluent monolayers. Cells were washed twice with assay buffer
(HBSS with 20 mMHEPES, pH 7.15) and incubated 2 h in 40 l/well assay
bufferwith0.1%DMSOat24°C, the sensorplatewas scanned, andabaseline
optical signature was recorded before incubating the indicated antagonists
for 30 min and adding 10 l of agonist dissolved in assay buffer containing
0.1% DMSO. DMR responses were monitored for at least 8000 s. Kinetic
results were analyzed using EnSpireWorkstation Software version 4.10 (En-
Spire Software), and curves were normalized with respect to the baseline.
In vivo VTA dendritic dopamine release. Male Sprague Dawley rats (3
months old; Charles River Laboratories) were used. Animals were
housed two per cage and kept on a 12 h dark/light cycle with food and
water available ad libitum. Experiments were performed during the light
cycle. All animals used in the study were maintained in accordance with
the guidelines of National Institutes of Health animal care, and the ani-
mal research conducted to perform this study was reviewed and ap-
proved by the National Institute on Drug Abuse Intramural Research
ProgramAnimal Care andUseCommittee (Protocol 12-BNRB-73). Rats
were deeply anesthetized with 3 ml/kg Equithesin [4.44 g of chloral hy-
drate, 0.972 g of Na pentobarbital, 2.124 g of MgSO4, 44.4 ml of propyl-
ene glycol, 12 ml of ethanol, and distilled H2O up to 100 ml of final
solution (National Institute on Drug Abuse Pharmacy)] and implanted
unilaterally in theVTA (coordinates inmm frombregmawith a 10° angle
in the coronal plane: anterior, 5.6; lateral, 2.4; vertical, 9) with a specially
designed microdialysis probe that allows the direct infusion of large
peptides within the sampling area. After surgery, rats were allowed to
recover in hemispherical CMA-120 cages (CMA Microdialysis)
equipped with two-channel overhead fluid swivels (Instech) con-
nected to a sample collector (CMA 470; CMA). Twenty-four hours
after implanting the probe, in the middle of the light period of the
light/dark cycle, experiments were performed on freely moving rats in
the same hemispherical home cages in which they recovered over-
night from surgery. An ACSF (in mM: 144 NaCl, 4.8 KCl, 1.7 CaCl2,
and 1.2 MgCl2) was pumped through the probe at a constant rate of 1
l/min. After a washout period of 90 min, dialysate samples were
collected at 20 min intervals. For peptide infusion, orexins and CRF
were dissolved in ACSF to a final concentration of 10 M, whereas
HIV TAT-fused peptides were dissolved in 0.1% DMSO in ACSF to a
final concentration of 30 M (TM1 and TM5) or 60 M (TM7). All
peptides were injected with a 1 l syringe (Hamilton) driven by an
infusion pump and coupled with silica tubing (73 m inner diameter;
Polymicro) to the microdialysis probe infusion port (dead volume, 40
nl), which was primed with ACSF and plugged during implantation.
All peptides were delivered at a rate of 16.6 nl/min. The OX1R antag-
onist SB334667 was dissolved in sterile saline and administered intra-
peritoneally (10 mg/kg) 40 min before peptide infusion. The CRF1R
antagonist NBI27914 was dissolved in 5%DMSO in water and admin-
istered intraperitoneally (10 mg/kg) 40 min before peptide infusion.
The 1R agonist PRE-084 was dissolved in ACSF at a concentration of
100 M and was perfused through the microdialysis probe (reverse
dialysis). Cocaine HCl was administered intraperitoneally 24 h before
the start of the microdialysis experiment at a dose of 15 mg/kg. At
the end of the experiment, rats were given an overdose of Equithesin, the
brains were extracted and fixed in formaldehyde, and probe placement was
verified using cresyl violet staining. Dopamine content was measured by
HPLC coupled with a coulometric detector (5200a Coulochem III; ESA).
Statistics. Sample sizes were between 5 and 10, which our previous
published work indicated are sufficient to perform appropriate statistical
analysis. Parametric statistics (unpaired t test and one-way or repeated-
measures ANOVA) were used, because the different groups analyzed
showed normality and homogeneity of variance. GraphPad Prism soft-
ware version 5 was used for the statistical analysis.
Results
Expression and functional characterization of heteromers
between OX1R and CRF1R in transfected cells
BRET and PLA experiments were performed in HEK-293T cells
transfected with OX1R–RLuc and CRF1R–YFP (Figs. 1A,B).
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These fusion proteins properly trafficked to the cell membrane,
as shown by confocal microscopy (Fig. 1C), and were functional,
as shown by comparing their ability to increase ERK1/2 phos-
phorylation with that of native receptors (Fig. 1D). BRET satura-
tion curves were obtained in cells expressing OX1R–RLuc and
increasing amounts of CRF1R–YFP (Fig. 1A), with BRETmax of
186 6 mBU and BRET50 of 54 7, indicating that these recep-
tors can indeed formheteromers. As a negative control, a low and
linear BRET was detected in cells expressing CRF1R–RLuc and
increasing amounts of GHS1aR fused to YFP (Fig. 1A). Accord-
ingly, receptor heteromers were also visualized as red spots by
using PLA in cells expressing OX1R–RLuc and CRF1R–YFP but
not in cells expressing CRF1R–RLuc and GHSR1a–YFP (Fig. 1B).
CRF or the OX1R agonist orexin-A induced ERK1/2 phos-
phorylation in cells coexpressing CRF1R and OX1R (Fig. 2A).
Orexin-A-induced signaling was inhibited by the OX1R antago-
Figure2. CRF1R–OX1Rheteromer function in transfectedHEK-293T cells.A–C, ERK1/2 phosphorylationwas performed in cells transfectedwith CRF1R–YFP cDNA (0.3g;B) or OX1R–RLuc cDNA
(0.4g;B) or both (A, C) pretreated (10min)with vehicle, the OX1R antagonist SB334667 (SB; 1M), or the CRF1R antagonist NBI27914 (NBI; 1M), followed by treatmentwithmedium, CRF (100
nM), orexin-A (50nM), or both for 7min (A,B) or for 2.5, 5, 7.5, 19, and15min (C). Values aremeansSEMsof five to six experimentspergroupandareexpressedaspercentageofbasal levels (100%;
dotted line). D, Akt phosphorylation was determined in cells transfected with CRF1R–YFP cDNA (0.3g) and OX1R–RLuc cDNA (0.4g), pretreated (10 min) with vehicle, the OX1R antagonist
SB334667 (SB; 1M), or the CRF1R antagonist NBI27914 (NBI; 1M), followed by treatment (7min)withmedium, CRF (100 nM), orexin-A (50 nM), or both. Values aremeans SEMs of six to eight
experiments per treatment and are expressed as percentage of basal levels (100%; dotted line). E, F,-Arrestin 2 recruitmentmeasured by BRET in cells transfectedwith CRF1R–YFP cDNA (0.3g;
E, white bars) or OX1R–YFP cDNA (0.4g; E, black bars), or both (F ) and-arrestin 2–RLuc cDNA (0.5g). Cells were pretreated (10min) with vehicle, SB334667 (SB; 1M), or NBI27914 (NBI; 1
M), followed by treatment (7 min) with CRF (100 nM), orexin-A (50 nM), or both. Values are means SEMs of five to six experiments per treatment. G, H, cAMP accumulation was determined in
cells transfected with CRF1R–YFP cDNA (0.3g; G, white bar) or OX1R–RLuc cDNA (0.4g; G, black bar), or both (H ). Cells were pretreated (10 min) with vehicle, the OX1R antagonist SB334667
(SB; 1M), or the CRF1RantagonistNBI27914 (NBI; 1M), followedby treatment (7min)withmedium, CRF (100nM), orexin-A (50nM), or both. Values aremeans SEMsof six to eight experiments
per treatment and expressed as increases of basal levels or as decreases of forskolin-induced cAMP accumulation (for orexin-A; 100%; dotted line). InA,B,D–F, andH, One-way ANOVA followed by
Bonferroni’s multiple comparison post hoc test shows significant single agonist effect versus basal values (*p 0.05, **p 0.01, and ***p 0.001), or CRF plus orexin-A treatment versus CRF or
orexin-A treatment ( #p 0.05) or antagonist plus agonist versus agonist with or without forskolin (FK; &p 0.05, &&p 0.01, and &&&p 0.001). In G, unpaired Student’s t test (two-tailed)
shows significant difference of single agonist treatment versus basal values (**p 0.01 and ***p 0.001).
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nist SB334867 and the CRF1R antagonist
NBI27914, that did notmodify basal levels
by themselves, and vice versa, CRF-
induced ERK1/2 phosphorylation was
antagonized by both NBI27914 and
SB334667. Thus, CRF1R–OX1R hetero-
mers display cross-antagonism, a prop-
erty seen in previous receptor heteromers
(Guitart et al., 2014; Moreno et al., 2014).
A negative crosstalk was also observed be-
cause ERK1/2 phosphorylation during
coactivation of both receptors was signif-
icantly lower compared with that induced
by single activation of either CRF1R or
OX1R (Fig. 2A). Cross-antagonism and
negative crosstalk were not attributable to
either the lack of ligand specificity, be-
cause they were not observed in cells ex-
pressing single receptors (Fig. 2B), or a
change in the shape of the time–response
curve of ERK1/2 phosphorylation (Fig. 2C).
Negative crosstalk and cross-antagonism
were also observed at the level of Akt
phosphorylation (Fig. 2D). -Arrestin re-
cruitment was also analyzed, because it
has been shown to mediate ERK1/2 and
Akt phosphorylation for several GPCRs
(Kovacs et al., 2009). Orexin-A but not
CRF significantly increased control BRET
values in cells expressing -arrestin
2–RLuc and OX1R–YFP. Similarly, CRF
but not orexin-A increased BRET values
in cells expressing -arrestin 2–RLuc and
CRF1R–YFP (Fig. 2E), indicating both the
specificity of the ligands and the ability of
these receptors to recruit -arrestin 2
when activated. Significantly, not only
CRF but also orexin-A significantly in-
creased BRET values in cells expressing
-arrestin 2–RLuc, CRF1R–YFP, and
OX1R (Fig. 2F). During coactivation with
both agonists CRF and orexin-A, a negative
crosstalk was observed at the level of
-arrestin 2 recruitment. Furthermore,
cross-antagonism could also be demon-
strated, and CRF-promoted and orexin-A-
promoted -arrestin 2 recruitment were
counteracted by SB334867 and NBI27914,
respectively (Fig. 2F).
Orexin-A decreased forskolin-stimulated
cAMPincells expressingOX1R, indicating re-
ceptor coupling to a Gi-protein, and CRF promoted an increase in
cAMP production in cells expressing CRF1R, indicating receptor
coupling to a Gs-protein (Fig. 2G). The same findings were ob-
served in cells coexpressingOX1R andCRF1R, suggesting that the
receptors can signal independently through their preferred
G-proteins in the CRF1R–OX1R heteromer (Fig. 2H). Cross-
antagonism could also be observed at the adenylyl-cyclase level in
cells coexpressing OX1R and CRF1R. Thus, orexin-A-induced
inhibition of forskolin-stimulated cAMP accumulation was
counteracted not only by theOX1R antagonist SB334867 but also
by the CRF1R antagonist NBI27914. Equally, CRF-induced
cAMP accumulation was counteracted by both NBI27914 and
SB334867 (Fig. 2H). A canonical Gs–Gi interaction at the
adenylyl-cyclase level could not be observed during coactivation
of both receptors with CRF and orexin-A, showing cAMP accu-
mulation similar to that obtained with CRF alone (Fig. 2H). This
would indicate a negative crosstalk by which CRF1R activation
counteracts OX1R signaling through Gi in the CRF1R–OX1R het-
eromer. These findings were supported with experiments using
label-free DMR technology, which allows measuring G-protein-
mediated signaling in living cells. Agonist-induced time–
response curves in the absence or presence of pertussis toxin
(PTX) or cholera toxin (CTX) were obtained in cells expressing
both OX1R and CRF1R (Fig. 3A). The maximum response in-
Figure 3. CRF1R–OX1R heteromer signaling detected by DMR. DMR was determined in HEK-293T cells stably transfected with
OX1R and transiently transfected with CRF1R cDNA (0.3 g; A, D, E) or only stably transfected with OX1R (C) or transiently
transfectedwith CRF1R cDNA (0.3g;B). Cellswerepretreated (overnight)with (A–D) vehicle, PTX (10ng/ml), or CTX (100ng/ml)
or vehicle, theOX1Rantagonist SB334667 (SB; 1M)or theCRF1RantagonistNB127914 (NBI; 1M), followedby treatment (7min)
with CRF (100 nM), orexin-A (50 nM), or both (E). A–C, Representative picometer shifts of reflected light wavelength (picometers)
versus time; each curve shows the mean of a representative optical trace experiment performed in triplicate. D, E, Maximum
responses are derived from the resulting picometer shifts of reflected lightwavelength (picometers) versus time curves. Values are
means SEMsof four to five experiments per group. One-wayANOVA followedbyBonferroni’smultiple comparisonpost hoc tests
show significant agonist effect versus basal values (***p 0.001), no significant effect of CRF plus orexin-A treatment versus CRF
or orexin-A treatment, and significant effect of agonist plus antagonist or toxin treatment versus agonist alone ( &&&p 0.001).
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duced by orexin-A or CRF (derived from
time–response curves) was significantly
inhibited with pretreatment with either
PTX or CTX (Fig. 3D). Conversely, in cells
only expressingCRF1R, the effect ofCRFwas
inhibitedbyCTXbutnotwithPTX(Fig. 3B),
whereas in cells only expressing OX1R, the
effect of orexin-Awas only inhibited by PTX
(Fig. 3C). These results demonstrate that the
heteromer can interact simultaneously with
both Gi- and Gs-proteins. Negative crosstalk
and cross-antagonismwere also observed by
DMR. The effect (maximum response) of
CRF or orexin-A was inhibited by both
NBI27914 andSB334867, and the coactivation
with CRF and orexin-A produced a lower re-
sponse than the one obtained by single activa-
tion (Fig. 3E). These results suggest strongly
that negative crosstalk and cross-antagonism
observed for G-protein-dependent and
-arrestin-dependent signaling pathways
constitute biochemical characteristics of
CRF1R–OX1R heteromers.
BiFC experiments (Fig. 4A) were per-
formed to check the ability of peptideswith
the amino acid sequence of OX1R TM do-
mains to destabilize CRF1R–OX1R hetero-
mer, as described recently for the dopamine
D1–D3 receptor heteromer (Guitart et al.,
2014). HIV TAT peptides fused to OX1R
TM1, TM5, and TM7 peptides were used.
Significant fluorescence could be detected in
HEK-293T cells transfected with CRF1R
fused to theN-terminal fragment of YFPVe-
nus (nVenus) and OX1R fused to the
C-terminal fragmentYFPVenus (cVenus) as
a result of YFP Venus reconstitution by
CRF1R–OX1R heteromerization. Treatment
with OX1R TM1 and TM5 peptides alone or
in combination, but not TM7, inhibitedYFP
Venus reconstitution, and the effect of TM1
plus TM5 was more pronounced than the
effect obtained by either peptide alone (Fig.
4B). ERK1/2 phosphorylation crosstalk and
cross-antagonism experiments were then
performed in cells pretreated with OX1R
TM1 (Fig. 4C) or TM5 (Fig. 4D) peptides.
Both peptides counteracted the negative
crosstalk and cross-antagonism (Fig. 4C,D).
Importantly, TM7 peptide, which was not
able to alter the structure ofCRF1R–OX1R in
BiFC experiments, was also ineffective at
counteracting the negative crosstalk and
cross-antagonism(Fig. 4E).Noneof thepep-
tides themselves significantly changedsignal-
ing fromeachof thereceptorswhenactivated
alonewith their respective agonists (Fig. 4C–
E). These results demonstrate that the nega-
tive crosstalk and cross-antagonism depend
onthe integrityof thequaternary structureof
the CRF1R–OX1R heteromer and, therefore,
that constitute biochemical characteristics
of the heteromer.
Figure 4. Effect of interfering synthetic peptides on the structure and function of CRF1R–OX1R heteromers. A, Scheme
showing BiFC. B, Disruptive effect of HIV TAT-fused peptides with the amino acid sequences of OX1R TM1, TM5, and TM7
on fluorescence emitted by HEK-293T cells cotransfected with CRF1R–nVenus cDNA (0.6M) and OX1R– cVenus cDNA (0.6
M). Values (fluorescence at 530 nm) are means SEMs of six to seven experiments per group. One-way ANOVA followed
by Bonferroni’s multiple comparison post hoc test shows significant differences versus control (Ctr; *p 0.05, **p
0.01, and ***p 0.001). C–E, Disruptive effect of HIV TAT-fused peptides on ERK1/2 phosphorylation in HEK-293T cells
transfected with CRF1R cDNA (0.3 g) and OX1R cDNA (0.4 g) preincubated (60 min) with OX1R TM1, TM5, or TM7 (4
M), pretreated (20 min) with vehicle, the OX1R antagonist SB334667 (SB; 1M), or the CRF1R antagonist NBI27914 (NBI;
1M), followed by treatment (7 min) with medium, CRF (100 nM), orexin-A (50 nM), or both. Values are means SEMs
of five to six experiments expressed as percentage of basal (100%; dotted line). One-way ANOVA followed by Bonferroni’s
multiple comparison post hoc test shows significant differences of agonist treatment versus basal values (**p 0.01 and
***p 0.001), CRF plus orexin-A treatment versus CRF or orexin-A treatment ( #p 0.05), one agonist plus antagonist
versus agonist alone ( &p 0.05 and &&p 0.01), or both agonists plus NBI27914 versus CRF, or both agonists plus SB
334867 versus orexin-A ( $p 0.05).
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Two CRF1R functional mutants were
used to provide some insight about the
conformational changes involved in the
negative crosstalk between ligands bind-
ing to the CRF1R–OX1R heteromer: (1) a
truncatedmutant (CRF1R433) that lacks a
large part of theN-terminal domain and is
not able to bind CRF but can still be acti-
vated by a small peptide that corresponds
to the N-terminal part of CRF (peptide
14b, which binds to the juxtamembrane
activating domain of CRF1R; Devigny et
al., 2011); and (2) a receptor that contains
a mutation in the third intracellular loop
and has enhanced constitutive activity
(CRF1R432). Both mutants were able to
form heteromers with OX1R as detected
by BRET experiments without significant
differences in BRETmax and BRET50 with
respect to the CRF1R (Fig. 5A,B). As ex-
pected, CRF or orexin-A did not induce
ERK1/2 phosphorylation in HEK-293T
cells expressing CRF1R433 alone (Fig.
5C). Orexin-A, but not CRF, was able to
signal in cells expressing CRF1R433–
OX1R heteromers, but orexin-A-induced
signaling was not modified by CRF or the
CRF1R antagonist NBI27914 (Fig. 5D,E).
Nevertheless, in these cells, peptide 14b
promoted ERK1/2 phosphorylation, and
a negative crosstalk was observed between
orexin-A and peptide 14b (Fig. 5F). These
results indicate that an active conforma-
tion of the CRF1R is involved with the
negative crosstalk of receptor agonists in
the CRF1R–OX1R heteromer. This was
further corroborated using the CRF1R432
mutant, which displays high constitutive
activity. Single expression of CRF1R432
showed increased basal ERK1/2 phos-
phorylation (compared with nontrans-
fected cells), which could not be increased
further by CRF (Fig. 5G). The same find-
ings were also obtained in cells expressing
CRF1R432 and OX1R (Fig. 5H). In addi-
tion, orexin-Adid not increaseMAPK sig-
naling, in agreement with the active
conformation of CRF1R facilitating an al-
losteric inhibition of the orexin-A signal-
ing (Fig. 5H).
CRF1R–OX1R heteromers in the VTA
control dendritic dopamine release
In rat VTA slices, orexin-A and CRF pro-
moted ERK1/2 phosphorylation (Fig.
6A), coactivation with orexin-A and CRF
showed negative crosstalk, and both the
CRF1R antagonist NBI27914 and the
OX1R antagonist SB334867, which do not
modify basal levels by themselves, antag-
onized the effect of orexin-A and CRF,
thus showing cross-antagonism (Fig. 6A).
Crosstalk and cross-antagonism disap-
Figure 5. Involvement of the active conformation of CRF1Rwith the negative crosstalk of receptor agonists in the CRF1R–OX1R
heteromer. A, B, BRET saturation experiments in HEK-293T cells transfected with OX1R–RLuc cDNA (0.2g) and increasing cDNA
amounts (0.05–0.5g) of CRF1R–YFP (circles), CRF1R433 mutant (triangles in A), or CRF1R432 mutant (triangles in B). BRET is
expressed asmBUas a function of 1000 the ratio between fluorescence of the acceptor (YFP) and Luciferase activity of the donor
(RLuc). Values aremeansSEMsof five to six replicationsof one independent experimentperpoint.C–F, ERK1/2phosphorylation
in HEK-293T cells transfected with CRF1R433mutant cDNA (0.3g; (B) alone or transfected with OX1R cDNA (0.4g) pretreated
(10 min) with vehicle, the OX1R antagonist SB334667 (SB; 1 M), or the CRF1R antagonist NBI27914 (NBI; 1 M), followed by
treatment (7min)with CRF (100 nM), orexin-A (50 nM), or both, orwith peptide 14b (10 nM; C–E). Values aremeans SEMs of five
to six experiments per group expressed as percentage of basal (100%). One-way ANOVA followed by Bonferroni’s multiple com-
parisonpost hoc test shows significant differences of single agonist treatment versus basal values (**p0.01 and ***p0.001),
CRF plus orexin-A treatment versus CRF or orexin-A treatment ( #p 0.05) or orexin-A plus SB334667 or peptide 14b versus
orexin-A alone ( &p 0.05 and &&&p 0.001). G, H, ERK1/2 phosphorylation in HEK-293T cells transfected with CRF1R432
mutant cDNA (0.3g; F ) alone or transfected with OX1R (0.4g) treated (7min) with vehicle or with CRF (100 nM), orexin-A (50
nM) or both (G). Values are means SEMs of five to six experiments per group expressed as percentage of basal values obtained
in nontransfected cells (100%).
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peared when VTA slices were treated with the CRF1R–OX1R de-
stabilizing peptides OX1R TM1 plus TM5 (10 M; Fig. 6B),
whereas the negative control TM7 peptide (at the same total pep-
tide concentration, 20 M) was ineffective (Fig. 6B), which dem-
onstrates the presence of CRF1R–OX1R heteromers in the VTA.
To investigate the functional role of CRF1R–OX1R hetero-
mers in the VTA, we analyzed dopamine release in the VTA using
in vivo microdialysis experiments (Fig. 6C–F). Dendritic dopa-
mine release bymesencephalic dopaminergic cells resembles that
of the terminal regions, possessing a similar uptake mechanism
and a finite releasable storage pool (Kita et al., 2009). Further-
more, local dopamine release in the VTA is a correlate of dopa-
minergic cell firing (Legault and Wise, 1999). Initial attempts to
perfuse orexin-A through the dialysis probe (reverse dialysis)
were unsuccessful, which included testing of different composi-
tions of ACSF and different dialysis membranes of different ma-
terials and different cutoff, as analyzed with mass-spectrometry
analysis of in vitro-recovered dialysates (data not shown). A spe-
cialized probe with an embedded silica infusion port was de-
signed (Fig. 7) that allowed simultaneous constant slow delivery
(1l/h) of large peptides (ligands and OX1R TM peptides) in the
same brain region where the microdialysis probe is sampling the
extracellular concentration of dopamine. VTA infusion of
orexin-A (10 M) for 60 min produced dopamine release, which
remained elevated1 h after withdrawal (Fig. 6D). The average
basal dialysate concentration of dopamine of a total of 121 ani-
mals was 2.37 0.15 nM (mean SEM). This effect was attrib-
utable to selective activation of OX1R, because it was not
reproduced by a 10 M infusion of the selective OX2R agonist
orexin-B (Sakurai et al., 1998; de Lecea et al., 1998) and was
counteracted by the previous systemic administration of an effec-
tive dose (10 mg/kg, i.p.) of the selective OX1R receptor antago-
nist SB334867 (Richards et al., 2008; Fig. 6D). The infusion of
CRF (10 M) or the systemic administration of an effective dose
(10 mg/kg, i.p.) of the CRF1R antagonist NBI27914 did not pro-
duce any significant change in the extracellular concentration of
dopamine, but both counteracted the effect of orexin-A (Fig. 6E),
demonstrating the negative crosstalk and cross-antagonism.
These results strongly suggest that dendritic VTA dopamine re-
lease is under the control of CRF1R–OX1R heteromers. This was
further demonstrated usingCRF1R–OX1Rdestabilizing peptides.
Infusion of OX1R TM1 (30 M) plus TM5 (30 M) peptides but
not the control TM7 peptide (at the same total peptide concen-
tration, 60 M) counteracted the orexin-A–CRF negative cross-
talk (Fig. 6F). The effect of the TM peptides was not long lasting,
probably because of a faster clearance compared with that of the
larger andmore hydrophilic orexin-A and CRFmolecules. These
results demonstrate that CRF1R–OX1R heteromers modulate
VTA dopamine release.
CRF1R–OX1R heteromers are signaling units that can be
modulated by cocaine in transfected cells and the VTA
In cells expressingCRF1R andOX1R, pretreatment for 2 hwith 30
M cocaine completely disrupted the negative crosstalk and
Figure 6. Expression and function of CRF1R–OX1R heteromers in the VTA. A, B, ERK1/2 phosphorylation in rat VTA slices preincubated (3 h) with vehicle (A) or HIV TAT-fused peptides with the
amino acid sequences of OX1R TM1 and TM5 (10M) or TM7 (20M) (30min) with or without the OX1R antagonist SB334667 (SB; 10M) or the CRF1R antagonist NBI27914 (NBI; 10M), or both,
followedby incubation (10min)with vehicle, CRF (1M), orexin-A (1M), or both (B). Values aremeansSEMsof five to six experimentsper groupexpressedaspercentageof basal values (100%).
One-way ANOVA followed by Bonferroni’smultiple comparison post hoc test shows significant differences of agonist treatment versus basal values (*p0.05, **p 0.01, and ***p 0.001), CRF
plus orexin-A treatment versus CRF or orexin-A treatment ( #p 0.05), or agonist plus antagonist treatment versus agonist alone ( &p 0.05 and &&p 0.01). C, Representative coronal section
of a rat brain (5.6 mm posterior from bregma), stained with cresyl violet, showing the track left by the tip of the modified microdialysis probe in the VTA (arrow). D, E, Dopamine (DA) levels in
dialysates sampled from the VTA after slow infusion (1l/h) of orexin-A (1l, 10M), orexin B (1l, 10M), and/or CRF (1l, 10M) after previous systemic (intraperitoneal) administration
of vehicle, SB334667 (SB; 10mg/kg; D), or NBI27914 (NBI; 10mg/kg; E) or with preinfusion and coinfusion (1l/h) of OX1R TM1 plus TM5 (30M) or TM7 (60M) (F ). Values are means SEMs
of 7–10 experiments per group and are expressed as percentage of basal values (average of first 3 values before orexin-A or CRF infusion). A repeated measures ANOVA followed by Bonferroni’s
multiple comparison post hoc test showed significant difference (filled symbols, p 0.05) versus the last basal values before orexin-A or CRF infusion. The same data on the effect of infusion of
orexin-A alone are shown in D–F for comparison.
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cross-antagonism between CRF1R and OX1R ligands on MAPK
signaling (Fig. 8A, black, bars) and -arrestin 2 recruitment (Fig.
8B, black bars) that was seen in the absence of cocaine (Fig. 8A,B,
white bars). Thus, cocaine blocks the allosteric intermolecular
interactions in the CRF1R–OX1R heteromers that conduce the
crosstalk and cross-antagonism between CRF1R and OX1R
ligands.
We next explored the effect of cocaine in the rat VTA. The
extracellular level of cocaine in the rat brain reached after phar-
macologically significant doses is estimated to be 15M (Pettit et
al., 1990). A higher cocaine concentration (100 M) was then
used to allow diffusion into the VTA slices. Cocaine pretreat-
ment for 4 h counteracted the negative crosstalk of orexin-A
and CRF on ERK1/2 phosphorylation. Furthermore, cross-
antagonism of SB334867 or NBI27914 on ERK1/2 phosphor-
ylation induced by CRF or orexin-A was not observed (Fig.
8C). Therefore, cocaine also disrupts the allosteric interac-
tions within the CRF1R–OX1R heteromer in the VTA.
1Rs mediate the disruptive effects of cocaine on
CRF1R–ORX1R heteromer function
It has been found recently that cocaine can disrupt allosteric in-
teractions between ligands in dopamine D1–histamine H3 recep-
tor (H3R) heteromers by acting on1Rs that oligomerize with the
heteromer (Moreno et al., 2014). We explored whether this
mechanism could be involved in the disruptive effects of cocaine
on CRF1R–ORX1R heteromer function. A saturable BRET curve
was obtained in HEK-293T cells expressing CRF1R–RLuc and
increasing concentrations of 1R–YFP (Fig. 9A), indicating a di-
rect interaction between 1R and CRF1R. Cocaine produced a
significant change in BRETmax and BRET50 BRET values (Fig.
9A), indicating a cocaine-induced change in the quaternary
structure of the 1R–CRF1R oligomers. Conversely, no signifi-
cant BRETwas detected in cells expressingOX1R–RLuc and1R–
YFP in the absence or presence of cocaine (Fig. 9B). These results
suggest that 1R can interact with CRF1R–OX1R heteromers by
binding to CRF1R in the heteromer. The heterotrimeric complex
expression was demonstrated with SRET (Fig. 10A; Carriba et al.,
2008). In HEK-293T cells expressing a constant amount of
OX1R–RLuc and 1R–YFP and increasing amounts of CRF1R–
Cherry, a net SRET saturation curve was obtained (Fig. 10B) with
an SRETmax of 0.31  0.01 mSU and a SRET50 of 0.08  0.01.
These results provide evidence for the existence of 1R–CRF1R–
OX1R oligomers. Cocaine produced a significant change in
SRETmax and SRET50 values (SRETmax of 0.19 0.03 mSU and a
SRET50 of 0.056  0.002), indicating a cocaine-induced change
in the quaternary structure of the 1R–CRF1R–OX1R oligomers.
The involvement of 1R in the effects of cocaine on CRF1R–
OX1R heteromers function in the VTA was demonstrated by us-
ing selective1R ligands. In VTA slices, pretreatment for 4 h with
the 1R agonist PRE-084 (Garce´s-Ramírez et al., 2011) counter-
acted the negative crosstalk on ERK1/2 phosphorylation detected
during CRF and orexin-A coadministration (Fig. 10C). More-
over, pretreatment with the 1R antagonist PD144418 (Akunne
et al., 1997) blocked the effect of cocaine, and the negative cross-
Figure 7. Microdialysis probewith infusion port.A, Magnification showing the length of the dialysismembrane between dotted lines (1mm).B, Amplification of different parts of the probe (on
a borosilicate glassmodel to show inner details). Internal tubing and infusion port aremade of fused silica (40mm internal diameter). The dialysismembrane (AN69) has a 20 kDamolecular weight
cutoff. Seals are made of epoxy resin. The design allows the infusing of large peptides in the same brain region being analyzed for extracellular levels of dopamine.
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talk between CRF and orexin-A was still present with preincuba-
tion of cocaine and PD144418 (Fig. 10D).
Cocaine exerts its stimulant effects predominantly by its abil-
ity to block the dopamine transporter (DAT; Kita et al., 2009). To
dissect the 1R effects in microdialysis experiments, we used the
selective 1R agonist PRE-084, which reproduced the effects of
cocaine in the in vitro experiments and has very low affinity for
DAT (Garce´s-Ramírez et al., 2011). Direct perfusion of the 1R
agonist PRE-084 (100 M) through the microdialysis probe did
not modify the extracellular concentration of dopamine (Fig.
10F) but counteracted the negative crosstalk between orexin-A
and CRF. Thus, in the presence of PRE-084, orexin-A plus CRF
produced an increase in extracellular dopamine that was larger
than the one induced by orexin-A alone (Fig. 10E). In fact, in the
presence of PRE-084, orexin-A was more
effective, particularly during the first two
samples (40 min) after its infusion. Inter-
estingly, CRF, which was ineffective by it-
self, also produced a prolonged significant
elevation of extracellular dopamine
during perfusion with the 1R agonist
(Fig. 10F ). These results match with the
in vitro experiments and indicate the ex-
istence of a negative crosstalk between
orexin-A and CRF, which is counter-
acted by 1R activation. These striking
results are in total agreement with
1R–CRF1R–OX1R oligomers modulat-
ing VTA dopamine release.
We then studied whether one single
administration of cocaine (15 mg/kg)
could also reproduce the effects of the
acute perfusion of the 1R agonist PRE-
084 attributable to a long-term disruption
of the allosteric interactions in the
CRF1R–OX1R heteromer, as demon-
strated recently for 1R–D1R–H3R oli-
gomers (Moreno et al., 2014). In fact, a
significant elevation in the extracellular
concentration of VTA dopamine was ob-
served after infusion of CRF or coinfusion
of orexin-A and CRF (Fig. 10G).
Discussion
Class B GPCR CRF1R has been shown
previously to homomerize (Milan-Lobo
et al., 2009) and also heteromerize with
the class A GPCRs for vasopressin and its
non-mammalian vertebrate homolog va-
sotocin in transfected cells (Mikhailova et
al., 2007; Murat et al., 2012). Similarly,
evidence has been reported for OX1R ho-
momerization and heteromerization in
artificial cell systems (Ellis et al., 2006;
Ja¨ntti et al., 2014). However, although co-
localized in the VTA, CRF1R–OX1R het-
eromerization has not been described,
and, in fact, it has been argued that inde-
pendent actions of CRF and orexin-A in
the VTA are involved in reinstatement of
cocaine seeking (Wang et al., 2009). In the
present study, we demonstrate the exis-
tence of functional CRF1R–OX1R hetero-
mers in transfected cells and the VTA, in
which they exert a significant functional control of dopaminergic
cells. By means of allosteric interactions within the CRF1R–OX1R
heteromer, CRF and orexin-A antagonize each other’s ability to signal
and promote VTA dendritic dopamine release, indicating that this
heteromer should play a significant role under stress conditions,
during concomitant CRF and orexin-A VTA release. Additional
important findings were the evidence for oligomerization of 1R
with the CRF1R–OX1R heteromer and the ability of1R agonists,
including cocaine, to modify the quaternary structure of the het-
eromer to block the functional allosteric interactions between
orexin-A and CRF within the heteromer.
Molecular interactions between CRF1R and OX1R were dem-
onstrated in HEK-293T cells by using different approaches,
Figure8. Cocaine-mediateddisruptionof negative crosstalk and cross-antagonismbetweenCRF1RandOX1R ligands in CRF1R–
OX1R heteromers in transfected cells and in the VTA. A, ERK1/2 phosphorylation in HEK-293T cells transfected with CRF1R–YFP
cDNA (0.3g) and OX1R–RLuc cDNA (0.4g) pretreated with (black bars) or without (white bars) cocaine (30M, 4 h) and (30
min) with vehicle, the OX1R antagonist SB334667 (SB; 1 M), or the CRF1R antagonist NBI27914 (NBI; 1 M), followed by
treatment (10min)with CRF (100nM) or orexin-A (50nM), or both. Values aremeans SEMsof six to seven experiments per group
expressed as percentage of basal values (100%). One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test
shows significant differences of agonist treatment versus basal values (**p 0.01, ***p 0.001), CRF plus orexin-A treatment
versus CRF or orexin-A treatment ( ##p 0.01), or agonist plus antagonist treatment versus agonist alone ( &&&p 0.001). B,
-Arrestin 2 recruitmentmeasuredbyBRET inHEK-293T cells transfectedwith CRF1R–YFP cDNA (0.3g) andOX1R cDNA (0.3g)
and-arrestin 2–RLuc cDNA (0.5g). Cells were pretreated (2 h) with cocaine (30M, black bars) or with medium (white bars)
and (10 min) with vehicle, SB334667 (SB; 1 M), or NBI27914 (NBI; 1 M), followed by treatment (7 min) with CRF (100 nM),
orexin-A (50nM), or both. Values aremeans SEMsof five to six experiments per group.One-wayANOVA followedbyBonferroni’s
multiple comparison post hoc test shows significant differences of agonist treatment versus basal (**p 0.01 and ***p 0.001)
or agonist plus antagonist treatment versus agonist alone ( &&&p 0.001). C, ERK1/2 phosphorylation in rat VTA slices preincu-
bated (4 h) with cocaine (100M, black bars) or with vehicle (white bars) and (30 min) with vehicle, SB334667 (SB; 10M), or
NBI27914 (NBI; 10M), followed by treatment (10 min) with CRF (1M), orexin-A (1M) or both. Values are means SEMs of
five to six experiments per group expressed as percentage of basal values (100%). One-way ANOVA followed by Bonferroni’s
multiple comparison post hoc test shows significant differences of agonist treatment versus basal values (**p 0.01 and ***p
0.001), CRF plus orexin-A treatment versus CRF or orexin-A treatment ( #p 0.05) or agonist plus antagonist treatment versus
agonist alone ( &p 0.05 and &&p 0.01).
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which included BRET, fluorescence complementation, and PLA,
but also additional demonstration came from results of signaling
experiments indicating the expression of CRF1R–OX1R hetero-
mers at the membrane level. To our knowledge, the ability of an
antagonist of one receptor to block the agonist-mediated signal-
ing of another receptor has only been reported in the frame of
receptor heteromerization (Ferre´ et al., 2014). Also, the ability of
orexin-A to induce an interaction between -arrestin 2–RLuc
and CRF1R–YFP indicates recruitment of -arrestin 2 to the
CRF1R–OX1R heteromer. Moreover, the surprising ability of
PTX to counteract Gs-mediatedCRF1R signaling and that of CTX
to block Gi-mediated OX1R signaling indicate that the CRF1R–
OX1R heteromer can interact simultaneously with bothGi andGs
proteins showing an interdependence of Gi and Gs protein func-
tion in the heteromer.
Demonstration of unique biochemical properties of a recep-
tor heteromer requires their dependence on the structural integ-
rity of the heteromer (Ferre´ et al., 2009, 2014), which can be
destabilized, for instance, by interfering synthetic peptides with
the amino acid sequence corresponding to some TM or intracel-
lular domains of one of the protomers (Azdad et al., 2009; He et
al., 2011; Guitart et al., 2014). BRET and complementation ex-
periments in transfected cells demonstrated that specific OX1R
TM peptides and 1R agonists significantly modify the quater-
nary structure of the CRF1R–OX1R heteromer. Therefore, both
were used as tools to interrogate the CRF1R–OX1R heteromer
function. In fact, both OX1R TM peptides and 1R agonists sig-
nificantly counteracted negative crosstalk and cross-antagonism
of CRF1R and OX1R ligands, demonstrating that they constitute
biochemical properties of the CRF1R–OX1R heteromer. The ap-
plication of the same tools in situ and in vivo, in VTA slices and in
microdialysis experiments, further demonstrated the presence of
CRF1R–OX1R heteromers in the VTA. The very different quan-
titative effect of OX1R TM peptides versus 1R agonists observed
in vivo, with a respective transient versus long-lasting (apparently
irreversible) destabilization of CRF1R–OX1R-heteromer func-
tion, should be related to the different molecular mechanisms
and different modifications of the quaternary structure of the
heteromer involved. Particularly significant will be the elucida-
tion of the apparently irreversible effect of 1R agonists, such as
cocaine.
An important amount of experimental data demonstrates the
involvement of 1R in many pharmacologic, including reward-
ing, effects of cocaine (Maurice and Su, 2009; Robson et al.,
2012). Recent studies describe a role of oligomerization of 1R
with D1R or D2R in the acute psychostimulants effects of cocaine
(Navarro et al., 2010, 2013) and with voltage-gated Kv1.2 potas-
sium channels in long-lasting behavioral responses (Kourrich et
al., 2013). Also, oligomerization of 1R, D1R, and H3Rs (1R–
D1R–H3R heteromers) has been involved in the neurotoxic ef-
fects of cocaine (Moreno et al., 2014). Interestingly, when
comparing the effects of cocaine binding with either 1R-D1R–
H3R or 1R–CRF1R–OX1R oligomers, a common mechanism
emerges, the loss of the allosteric interactions between ligands in
the heteromer.
The present results strongly suggest that CRF1R–OX1R het-
eromers localized in the VTA convey the previously established
significant control of dopaminergic cell function by CRF and
orexin-A in cocaine-treated animals. The counteraction of the
negative crosstalk between orexin-A and CRF in the VTA by the
simultaneous application of the 1R agonist PRE-084 or by
the previous administration of cocaine provides a mechanism by
which CRF can only induce VTA dendritic dopamine release in
animals exposed previously to cocaine (Wang et al., 2005). Under
these conditions, CRF1R-mediated signaling is not inhibited by a
tonic activation of OX1R by endogenous orexin-A. Counterac-
tion of the allosteric interactions between agonists in the CRF1R–
OX1Rheteromer can also explain the apparent CRF-independent
ability of orexin-A to release dopamine in the VTA and to induce
cocaine seeking (Wang et al., 2009). Remarkably, in the present
study, cocaine produced amodification of CRF1R–OX1R hetero-
mer function that was observed 24 h after one single systemic
administration. Very similar findings were reported recently for
1R–D1R–H3R oligomers, in which the ability of H3R ligands to
modulate D1R-mediated signaling was also disrupted 24 h after
one single systemic administration of cocaine (Moreno et al., 2014).
Therefore, one single administration could explain some effects of
cocaine attributed previously to its repeated administration.
Of the many new questions this study raises is the identifica-
tion of the precise localization ofCRF1R–OX1Rheteromers in the
VTA. Both receptors are potentially colocalized in dopaminergic
cells and their glutamatergic afferents Borgland et al., 2010), in
whichCRF1R–OX1R heteromers could directly or indirectly con-
trol the extracellular levels of dopamine in the VTA. Second, our
data indicate that, under basal conditions, the effects of CRF and
orexin-A in the VTA are interdependent and mediated by
CRF1R–OX1R heteromers, but they also suggest that endogenous
1R ligands should be able to act as cocaine and therefore pro-
mote independent effects of CRF and orexin-A. Those ligands
and the conditions under which they are produced in the VTA
Figure 9. Interaction of 1R with CRF1R. BRET saturation experiments in HEK-293T cells
transfectedwith CRF1R-RLuc cDNA (0.3g;A) or OX1R–RLuc cDNA (0.4g;B) with increasing
amounts of 1R–YFP cDNA (0.06–0.7 g), in the absence (black curves) or presence (red
curves) of cocaine (30M). BRET, expressed as mBU, is given as a function of 1000 the ratio
between the fluorescence of the acceptor (YFP) and the Luciferase activity of the donor (RLuc).
Values are means SEMs of five to six experiments.
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still need to be determined. Third is to understand the potential
changes in 1R–CRF1R–OX1R oligomers in acute versus long-
term exposure to cocaine. It has been shown that repeated co-
caine exposure increases the levels of 1R in the brain (Robson et
al., 2012), and cocaine-mediated upregulation of striatal 1R has
been reported to increase the presence of 1–Kv1.2 oligomers at
the plasma membrane, which has been suggested to be involved
in sensitization to its psychostimulants effects (Kourrich et al.,
2013). Therefore, upregulation of 1R in the VTA could increase
the proportion of1R–CRF1R–OX1R oligomers, leading tomore
profound cocaine-induced changes in the control of VTA den-
dritic dopamine release by CRF and orexin-A. Those changes
could explain the CRF1R-dependent augmented cocaine seeking
in response to stress or CRF delivered into the VTA after long-
access self-administration (Blacktop et al., 2011). Altogether, the
present study demonstrates a significant functional and pharma-
cological role of 1R in the modulation of CRF1R–OX1R hetero-
mers during physiological conditions and under conditions of
acute cocaine administration and withdrawal. Addressing the
study of 1R–CRF1R–OX1R oligomers in animal models of psy-
chostimulant abuse should provide significant additional infor-
mation that would support their role as new therapeutic targets.
References
AkunneHC,Whetzel SZ,Wiley JN,CorbinAE,NintemanFW,TecleH, Pei Y,
Pugsley TA, Heffner TG (1997) The pharmacology of the novel and se-
lective sigma ligand, PD 144418. Neuropharmacology 36:51–62.
CrossRef Medline
AzdadK, Gall D,Woods AS, Ledent C, Ferre´ S, Schiffmann SN (2009) Dopamine
D2andadenosineA2AreceptorsregulateNMDA-mediatedexcitationinaccum-
Figure 10. Involvement of 1R in the disruptive effect of cocaine on CRF1R–OX1R heteromer function. A, Scheme showing SRET (see Results). B, SRET saturation experiments in
HEK-293T cells expressing a constant amount of OX1R–RLuc cDNA (0.2g of cDNA transfected) and1R–YFP cDNA (0.3g) and increasing amounts of CRF1R–Cherry cDNA (0.05– 0.6
g) in controls (black curve) or cocaine-treated (30 min, 30 M; red curve) cells. SRET, expressed as mSU, is given as a function of the ratio between the fluorescence of the acceptor
(Cherry) and the Luciferase activity of the donor (RLuc). Values are means SEMs of seven to eight replications of one independent experiment per point. C, ERK1/2 phosphorylation in
rat VTA slices preincubated (4 h) with the1R agonist PRE-084 (1M), followed by treatment (10 min) with CRF (1M), orexin-A (1M), or both. D, ERK1/2 phosphorylation in rat VTA
slices preincubated (4 h) with the 1R antagonist PD144418 (1M), with or without cocaine (100M), followed by treatment (10 min) with CRF (1M), orexin-A (1M), or both. In C
and D, values are means SEMs of five to six experiments per group expressed as percentage of basal values (100%). One-way ANOVA followed by Bonferroni’s multiple comparison post
hoc test showed significant differences versus basal (*p 0.05) and CRF plus orexin-A treatment versus CRF or orexin-A treatment ( #p 0.05). E–G, Dopamine (DA) levels in dialysates
sampled from the VTA after slow infusion (1 l/h) of orexin-A (1 l, 10 M) and/or CRF (1 l, 10 M) with preinfusion and coinfusion of the 1R agonist PRE-084 (PRE; 100 M) or
previous systemic (intraperitoneal) administration of cocaine (COC; 15 mg/kg; 24 h before the microdialysis experiment). Values are means SEMs of 7–10 experiments per group and
are expressed as percentage of basal values (average of first 3 values before orexin-A or CRF infusion). A repeated-measures ANOVA (including only the basal value before orexin-A or CRF
infusion) followed by Bonferroni’s multiple comparison post hoc test showed significant differences (filled symbols, p 0.05) versus the last basal values before orexin-A or CRF infusion.
Data on the effect of infusion of orexin-A alone in E are the same shown in Figure 6D–F.
Navarro et al. • Orexin–CRF Receptor Heteromers in the VTA J. Neurosci., April 29, 2015 • 35(17):6639–6653 • 6651
bens neurons through A2A-D2 receptor heteromerization. Neuropsychophar-
macology 34:972–986.CrossRefMedline
Blacktop JM, Seubert C, Baker DA, Ferda N, Lee G, Graf EN, Mantsch JR
(2011) Augmented cocaine seeking in response to stress orCRFdelivered
into the ventral tegmental area following long-access self-administration
is mediated by CRF receptor type 1 but not CRF receptor type 2. J Neu-
rosci 31:11396–11403. CrossRef Medline
Borgland SL, Ungless MA, Bonci A (2010) Convergent actions of orexin/
hypocretin and CRF on dopamine neurons: emerging players in addic-
tion. Brain Res 1314:139–144. CrossRef Medline
Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, de
Lecea L (2005) Role for hypocretin in mediating stress-induced rein-
statement of cocaine-seeking behavior. Proc Natl Acad Sci U S A 102:
19168–19173. CrossRef Medline
Carriba P, NavarroG, Ciruela F, Ferre´ S, Casado´ V, Agnati L, Corte´s A,Mallol
J, Fuxe K, Canela EI, Lluís C, Franco R (2008) Detection of heteromer-
ization of more than two proteins by sequential BRET-FRET. Nat Meth-
ods 5:727–233. CrossRef Medline
de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C,
Battenberg EL,GautvikVT, Bartlett FS 2nd, FrankelWN, van denPol AN,
Bloom FE, Gautvik KM, Sutcliffe JG (1998) The hypocretins: hypo-
thalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad
Sci U S A 95:322–327. CrossRef Medline
Devigny C, Perez-Balderas F, Hoogeland B, Cuboni S,Wachtel R,Mauch CP,
Webb KJ, Deussing JM, Hausch F (2011) Biomimetic screening of
class-B G protein-coupled. J Am Chem Soc 133:8927–8933. CrossRef
Medline
Ellis J, Pediani JD, Canals M, Milasta S, Milligan G (2006) Orexin-1
receptor-cannabinoid CB1 receptor heterodimerization results in both
ligand-dependent and -independent coordinated alterations of receptor
localization and function. J Biol Chem 281:38812–38824. CrossRef
Medline
Ferre´ S, Baler R, BouvierM, CaronMG, Devi LA, Durroux T, Fuxe K, George
SR, Javitch JA, Lohse MJ, Mackie K, Milligan G, Pfleger KD, Pin JP,
Volkow ND, Waldhoer M, Woods AS, Franco R (2009) Building a new
conceptual framework for receptor heteromers. Nat Chem Biol 5:131–
134. CrossRef Medline
Ferre´ S, Casado´ V, Devi LA, Filizola M, Jockers R, Lohse MJ, Milligan G, Pin JP,
Guitart X (2014) Protein-coupled receptor oligomerization revisited: func-
tional and pharmacological perspectives. Pharmacol Rev 66:413–434.
CrossRefMedline
Garce´s-Ramírez L,Green JL,Hiranita T, Kopajtic TA,MereuM,ThomasAM,
Mesangeau C, Narayanan S, McCurdy CR, Katz JL, Tanda G (2011)
Sigma receptor agonists: receptor binding and effects on mesolimbic do-
pamine neurotransmission assessed by microdialysis. Biol Psychiatry 69:
208–217. CrossRef Medline
Guitart X, Navarro G, Moreno E, Yano H, Cai NS, Sa´nchez-Soto M, Kumar-
Barodia S, Naidu YT, Mallol J, Corte´s A, Lluís C, Canela EI, Casado´ V,
McCormick PJ, Ferre´ S (2014) Functional selectivity of allosteric inter-
actions within GPCR oligomers: the dopamine D1–D3 receptor hetero-
tetramer. Mol Pharmacol 86:417–429. CrossRef Medline
He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, Li Q, Yang H, Luo J,
Li ZY, Wang Q, Lu YJ, Bao L, Zhang X (2011) Facilitation of -opioid
receptor activity by preventing -opioid receptor-mediated codegrada-
tion. Neuron 69:120–131. CrossRef Medline
Ja¨ntti MH, Mandrika I, Kukkonen JP (2014) Human orexin/hypocretin re-
ceptors form constitutive homo- and heteromeric complexes with each
other and with human CB1 cannabinoid receptors. Biochem Biophys Res
Commun 445:486–490. CrossRef Medline
Kita JM,Kile BM, Parker LE,WightmanRM (2009) In vivomeasurement of
somatodendritic release of dopamine in the ventral tegmental area. Syn-
apse 63:951–960. CrossRef Medline
Kourrich S, Hayashi T, Chuang JY, Tsai SY, Su TP, Bonci A (2013) Dynamic
interaction between sigma-1 receptor and Kv1.2 shapes neuronal and
behavioral responses to cocaine. Cell 152:236–247. CrossRef Medline
Kovacs JJ, Hara MR, Davenport CL, Kim J, Lefkowitz RJ (2009) Arrestin
development: emerging roles for beta-arrestins in developmental signal-
ing pathways. Dev Cell 17:443–458. CrossRef Medline
Legault M, Wise RA (1999) Injections of N-methyl-D-aspartate into the
ventral hippocampus increase extracellular dopamine in the ventral teg-
mental area and nucleus accumbens. Synapse 31:241–249. CrossRef
Medline
Lodge DJ, Grace AA (2005) Acute and chronic corticotropin-releasing factor 1
receptor blockade inhibits cocaine-induced dopamine release: correlation
with dopamine neuron activity. J Pharmacol Exp Ther 314:201–206.
CrossRefMedline
Lu L, Liu Z, Huang M, Zhang Z (2003) Dopamine-dependent responses to
cocaine depend on corticotropin-releasing factor receptor subtypes.
J Neurochem 84:1378–1386. CrossRef Medline
Mahler SV,MoormanDE, Smith RJ, JamesMH, Aston-Jones G (2014) Mo-
tivational activation: a unifying hypothesis of orexin/hypocretin function.
Nat Neurosci 17:1298–1303. CrossRef Medline
Maurice T, Su TP (2009) The pharmacology of sigma-1 receptors. Pharma-
col Ther 124:195–206. CrossRef Medline
MikhailovaMV,MayeuxPR, JurkevichA,KuenzelWJ,Madison F, Periasamy
A, Chen Y, Cornett LE (2007) Heterooligomerization between vasoto-
cin and corticotropin-releasing hormone (CRH) receptors augments
CRH-stimulated 3,5-cyclic adenosine monophosphate production.
Mol Endocrinol 21:2178–2188. CrossRef Medline
Milan-Lobo L, Gsandtner I, Gaubitzer E, Ru¨nzler D, Buchmayer F, Köhler
G, Bonci A, Freissmuth M, Sitte HH (2009) Subtype-specific differ-
ences in corticotropin-releasing factor receptor complexes detected by
fluorescence spectroscopy. Mol Pharmacol 76:1196–1210. CrossRef
Medline
Moreno E, Moreno-Delgado D, Navarro G, Hoffmann HM, Fuentes S,
Rosell-Vilar S, Gasperini P, Rodríguez-Ruiz M, Medrano M, Mallol J,
Corte´s A, Casado´ V, Lluís C, Ferre´ S, Ortiz J, Canela E, McCormick PJ
(2014) Cocaine disrupts histamine H3 receptor modulation of dopa-
mine D1 receptor signaling: 1-D1–H3 receptor complexes as key targets
for reducing cocaine’s effects. J Neurosci 34:3545–3558. CrossRef
Medline
Murat B, Devost D, Andre´s M, Mion J, Boulay V, Corbani M, Zingg HH,
Guillon G (2012) V1b and CRHR1 receptor heterodimerization medi-
ates synergistic biological actions of vasopressin and CRH. Mol Endocri-
nol 26:502–520. CrossRef Medline
Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, Mallol J,
Corte´s A, Casado´ V, Canela EI, Ortiz J, Fuxe K, Lluís C, Ferre´ S, Franco R
(2010) Direct involvement of sigma-1 receptors in the dopamine D1
receptor-mediated effects of cocaine. Proc Natl Acad Sci U S A 107:
18676–18681. CrossRef Medline
Navarro G,Moreno E, Bonaventura J, Brugarolas M, Farre´ D, Aguinaga D,
Mallol J, Corte´s A, Casado´ V, Lluís C, Ferre S, Franco R, Canela E,
McCormick PJ (2013) Cocaine inhibits dopamine D2 receptor sig-
naling via sigma-1-D2 receptor heteromers. PLoS One 8:e61245.
CrossRef Medline
Pettit HO, Pan HT, Parsons LH, Justice JB Jr (1990) Extracellular concen-
trations of cocaine and dopamine are enhanced during chronic cocaine
administration. J Neurochem 55:798–804. CrossRef Medline
Richards JK, Simms JA, Steensland P, Taha SA, Borgland SL, Bonci A, Bartlett
SE (2008) Inhibition of orexin-1/hypocretin-1 receptors inhibits
yohimbine-induced reinstatement of ethanol and sucrose seeking in
Long-Evans rats. Psychopharmacology 199:109–117. CrossRef Medline
Robson MJ, Noorbakhsh B, Seminerio MJ, Matsumoto RR (2012) Sigma-1
receptors: potential targets for the treatment of substance abuse. Curr
Pharm Des 18:902–919. CrossRef Medline
Rodaros D, Caruana DA, Amir S, Stewart J (2007) Corticotropin-releasing
factor projections from limbic forebrain and paraventricular nucleus of
the hypothalamus to the region of the ventral tegmental area. Neurosci-
ence 150:8–13. CrossRef Medline
Saal D, Dong Y, Bonci A, Malenka RC (2003) Drugs of abuse and stress
trigger a common synaptic adaptation in dopamine neurons. Neuron
37:577–582. CrossRef Medline
Sakurai T (2014) The role of orexin in motivated behaviours. Nat Rev Neu-
rosci 15:719–731. CrossRef Medline
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Wil-
liams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham
RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA,
ElshourbagyNA, BergsmaDJ, YanagisawaM (1998) Orexins and orexin
receptors: a family of hypothalamic neuropeptides and G protein-
coupled receptors that regulate feeding behavior. Cell 92:573–585.
CrossRef Medline
Sarnyai Z, Shaham Y, Heinrichs SC (2001) The role of corticotropin-
releasing factor in drug addiction. Pharmacol Rev 53:209–243.
Medline
6652 • J. Neurosci., April 29, 2015 • 35(17):6639–6653 Navarro et al. • Orexin–CRF Receptor Heteromers in the VTA
Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein
transduction: delivery of a biologically active protein into the mouse.
Science 285:1569–1572. CrossRef Medline
Shaham Y, Erb S, Leung S, Buczek Y, Stewart J (1998) CP-154,526, a
selective, non-peptide antagonist of the corticotropin-releasing fac-
tor1 receptor attenuates stress-induced relapse to drug seeking in
cocaine- and heroin-trained rats. Psychopharmacology 137:184–190.
CrossRef Medline
Ungless MA, Singh V, Crowder TL, Yaka R, Ron D, Bonci A (2003)
Corticotropin-releasing factor requiresCRFbinding protein to potentiate
NMDA receptors via CRF receptor 2 in dopamine neurons. Neuron 39:
401–407. CrossRef Medline
Wang B, Shaham Y, Zitzman D, Azari S, Wise RA, You ZB (2005) Cocaine
experience establishes control of midbrain glutamate and dopamine by
corticotropin-releasing factor: a role in stress-induced relapse to drug
seeking. J Neurosci 25:5389–5396. CrossRef Medline
Wang B, You ZB, Rice KC, Wise RA (2007) Stress-induced relapse to co-
caine seeking: roles for the CRF(2) receptor and CRF-binding protein in
the ventral tegmental area of the rat. Psychopharmacology 193:283–294.
CrossRef Medline
Wang B, You ZB, Wise RA (2009) Reinstatement of cocaine seeking by
hypocretin (orexin) in the ventral tegmental area: independence from the
local corticotropin-releasing factor network. Biol Psychiatry 65:857–862.
CrossRef Medline
Navarro et al. • Orexin–CRF Receptor Heteromers in the VTA J. Neurosci., April 29, 2015 • 35(17):6639–6653 • 6653
